Hemispherx Biopharma, Inc. announced that it continues to build its manufacturing and scientific capabilities with the promotion of Carol Smith, Ph.D., as the Chief Manufacturing Officer and Deputy Chief Scientific Officer. In this new role, which is critical to the company’s plan to increase Ampligen® production, Dr. Smith will be responsible for all manufacturing processes of Ampligen® and Alferon® to satisfy the Early Access Program (EAP) for pancreatic cancer and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) as well as U.S.-based compassionate care programs such as AMP-511. She will work closely with Dr. David Strayer, Chief Scientific and Medical Officer, to assist in managing the Company's scientific, technological, and research operations. Prior to this promotion, Dr. Smith held several positions since joining the Company in 1991, including Manager of Quality, VP of Manufacturing and Process Development, and manager of Quality Control. She has more than 35 years of experience in the biopharmaceutical industry involving the production of immuno-modulatory agents comprised of natural interferons and nucleic acids.